

Oncology Today with Dr Neil Love: Management of Pancreatic Cancer
(Presentation Video)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following eligibility criteria was applied in the POLO trial evaluating maintenance olaparib for patients with metastatic pancreatic cancer who had not experienced disease progression on first-line platinum-based chemotherapy?**
 - Eligible patients had germline BRCA mutations only
 - Eligible patients had either somatic or germline BRCA mutations
- 2. The Phase III AFACT trial comparing adjuvant gemcitabine/*nab* paclitaxel to gemcitabine alone for surgically resected pancreatic cancer reported which outcome with respect to the primary endpoint of disease-free survival in the gemcitabine/*nab* paclitaxel arm?**
 - Statistically significant improvement
 - No statistically significant improvement
- 3. Which of the following statements is true regarding patients with pancreatic cancer who have germline BRCA mutations?**
 - They are sensitive to platinum-based chemotherapy and are candidates for PARP inhibition
 - They are candidates for PARP inhibition but do not respond well to platinum-based chemotherapy
- 4. What is the mechanism of action of the novel agent devimistat?**
 - Damages DNA
 - Targets mitochondrial enzymes involved in metabolism
 - Inhibits immune checkpoints